London, Jun 5, 2019 (Issuewire.com) – Mr. Brad Stott, a co-founder of Truverra Inc., was diagnosed with stage three prostate cancer in 2010. “At that time there was very little research being done in this field,” Brad commented. Inspired by his own success, an approach that included diet, specialized supplements, exercise, and cannabinoid therapy, Mr. Stott became passionate about scientific developments in cannabinoid and terpene R&D. He is now leading partnership initiatives for Truverra Inc. in Canada, liaising with academic institutions and patient advocacy groups as well as government to bring Truverra’s name and research ambitions to the fore.
Truverra Inc. is based in Toronto and has an approach that is both unique and focused. The team has been working hard, since 2013, towards its overarching goal – To be a global leader in the development, production, and marketing of cannabis and hemp-derived medicinal products with clinically proven efficacy. It’s wholly-owned Canadian subsidiary, Canadian Clinical Cannabinoids Inc., is a Health Canada approved Licenced Producer. It’s aptly named Cannabis Innovation Centre boosts extensive expertise in extraction, analytics, intellectual property, genetics, formulation development, and pharmaceutical business development.
Truverra Inc. seems well positioned to reach its objective of providing a value-added range of hemp and cannabis-derived products for the Canadian market. As if that weren’t already a large enough undertaking, Truverra’s Cannabis Innovation Center in Toronto will soon submit an application to Health Canada to expand its activities to include the production of extracts, distillates, and concentrates. These expanded capabilities may open new product opportunities that incorporate product features normally found in traditional pharmaceutical products such as quick onset, batch-to-batch uniformity, convenient defined dosing, and superior bio-availability.
TRUVERRA (EUROPE) BV – A European Approach to Hemp-derived CBD Wellness
Truverra is not just about Canada. Over in Europe, Truverra (Europe) BV., a wholly owned subsidiary of Truverra Inc., is equally focused and energetic.
Truverra (Europe) BV is pleased to announce the launch of its higher-quality Cannabidiol (CBD) portfolio of Supplements, Medical Devices, and Cosmetics in the UK and Netherlands – all of these extracted from Certified prime quality European hemp. (Cannabis Sativa L). In addition to its ‘made in Europe’ approach, many of these formulations have been developed to ensure consumers receive the maximum potential from their CBD products by utilizing a liposomal delivery system that allows a higher percentage of CBD to reach the endocannabinoid system in a shorter period of time.
Dr. Colin Jennison, a former organic chemistry professor at Ryerson University and VP of Laboratory Operations for Truverra Inc, stated, “there are over 140 cannabinoids and over 200 terpenes that have been discovered in the past 50 years. We are only beginning to understand the ways that these remarkable compounds interact with the body and how they can help in a wide range of medical conditions. More research is needed in this exciting area and Truverra is pleased to be at the forefront of this effort with like-minded partners in Europe.”
Over the coming months, Truverra plans to open up its product range to other European countries. Truverra products are available to consumers online at www.truverra.eu and will soon be available through distributors and retailers across Europe.
For more details on partnership opportunities with Truverra, please contact John Harrison, Business Development Director at email@example.com John can also put you in contact with colleague’s over in Canada for contacts related to research and applicable collaboration interests.
London Canna Group firstname.lastname@example.org
March 18, 2019
Truverra Inc. is pleased to announce that its wholly-owned subsidiary, Canadian Clinical Cannabinoids Inc. (the “Company” or “CCC”) has obtained a “Standard Cultivation” licence and a “Sale for Medical Purposes” licence pursuant to the Cannabis Act and Cannabis Regulations. The licences give CCC the ability to begin cultivation at its fully constructed 5,000 square-foot, state-of-the-art facility in Scarborough, Ontario.
The Company reached this significant milestone with dedication from its management team, consultants and shareholders. CCC is excited to commence cultivation and analytical testing on its unique and rare cultivars.
About Canadian Clinical Cannabinoids Inc.
Canadian Clinical Cannabinoids Inc. is the home of the Cannabis Innovation Centre and is a wholly-owned subsidiary of Truverra Inc. Starting with cultivation and analytical testing, the Company is intent on being the preferred partner to the cannabis industry for genomic profiling, extraction, purification, processing, and product research and development.
CCC recognizes that significant achievements come to life through partnership and collaboration. The Company is committed to working closely with licensed producers, researchers, the food and beverage industry, and pharmaceutical companies to meet the growing demand for high quality products. CCC’s strong customer service orientation and unwavering commitment to upholding the highest quality standards define its relationships with partners and clients.About Truverra Inc.Truverra Inc. is the the parent company of Canadian Clinical Cannabinoids Inc. and seeks global leadership in the development, production and marketing of hemp and cannabis derived medicinal products with clinically proven efficacy. Through its subsidiaries in Europe and the United States, Truverra Inc. is on track to launch a broad portfolio of innovative, high-quality hemp derived CBD wellness products in Q2 2019.
For Further Information: